title: Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
abstract: OBJECTIVE
  To determine comparative in vitro activity of sitafloxacin against clinical isolates of bacteria from Thai patients with urinary tract infection and those with lower respiratory tract infection.
  
  
  METHODS
  1,255 clinical isolates of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterococcus spp, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis isolated from different Thai patients with urinary tract infection and those with lower respiratory tract infection in 2010 were included. The minimum inhibitory concentrations (MICs) of sitafloxacin, ciprofloxacin, levofloxacin, moxifloxacin, imipenem, amikacin, ampicillin, ceftazidime, ceftriaxone, penicillin, piperacillin/tazobactam, vancomycin, azithromycin and trimethoprim/sulfamethoxazole were determined by standard agar dilution method.
  
  
  RESULTS
  The MIC50 and MIC90 values of sitafloxacin against all tested bacteria were lowest when compared with those of levofloxacin, ciprofloxacin and moxifloxacin. Sitafloxacin was active against 51% of methicillin-resistant S. aureus (MRSA) isolates. The activity of sitafloxacin against multidrug-resistant (MDR) Gram-negative bacteria, such as, extended spectrum beta-lactamase (ESBL)-producing E. coli and K. pneumomiae, P. aeruginosa and A. baumannii was comparable to or more than that of some beta-lactam/beta-lactamase inhibitors, cephalosporins or carbapenems.
  
  
  CONCLUSIONS
  Sitafloxacin is more active than levofloxacin, ciprofloxacin and moxifloxacin against isolated bacteria from Thai patients with urinary tract and lower respiratory infections including antibiotic resistant bacteria, such as MRSA, ESBL-producing Gram-negatives, carbapenem-resistant A. baumannii.
authors.affiliation: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Surapee
authors.initials: S
authors.lastname: Tiengrim
authors.forename: Danabhand
authors.initials: D
authors.lastname: Phiboonbanakit
authors.forename: Sudaluck
authors.initials: S
authors.lastname: Thunyaharn
authors.forename: Woraphot
authors.initials: W
authors.lastname: Tantisiriwat
authors.forename: Somchai
authors.initials: S
authors.lastname: Santiwatanakul
authors.forename: Wattanachai
authors.initials: W
authors.lastname: Susaengrat
authors.forename: Nuttiya
authors.initials: N
authors.lastname: Srisurat
authors.forename: Amnat
authors.initials: A
authors.lastname: Malithong
authors.forename: Praphatsorn
authors.initials: P
authors.lastname: Srisangchan
authors.forename: Visanu
authors.initials: V
authors.lastname: Thamlikitkul
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001372:Aza Compounds / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013785:Thailand; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D002939:Ciprofloxacin; D064704:Levofloxacin; C076246:sitafloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin